Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
| Dec 25 | Dec 24 | Dec 23 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -332.00K | $ -545.00K | $ -835.00K | $ -777.00K | $ -546.00K |
| Operating Income | $ -15.00M | $ -15.54M | $ -29.39M | $ -25.80M | $ -19.29M |
| EBITDA | $ -14.67M | $ -14.47M | $ -28.22M | $ -25.02M | $ -18.74M |
| Net Income | $ 1.24B | $ -15.01M | $ -29.07M | $ -31.06M | $ -14.47M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 5.87M | $ 23.61M | $ 27.32M | $ 48.12M | $ 84.13M |
| Total Assets | $ 2.33B | $ 27.69M | $ 36.83M | $ 67.64M | $ 95.15M |
| Total Debt | $ 641.00K | $ 534.00K | $ 1.03M | $ 4.85M | $ 617.00K |
| Net Debt | $ -1.37M | $ -2.77M | $ 219.00K | $ -42.98M | $ -10.59M |
| Total Liabilities | $ 392.05M | $ 4.10M | $ 6.75M | $ 10.80M | $ 10.11M |
| Stockholders' Equity | $ 1.93B | $ 23.59M | $ 30.08M | $ 56.84M | $ 85.04M |
| Cash Flow | |||||
| Free Cash Flow | $ -10.48M | $ -13.11M | $ -23.76M | $ -32.08M | $ -19.17M |
| Operating Cash Flow | $ -10.42M | $ -13.01M | $ -23.52M | $ -23.95M | $ -17.54M |
| Investing Cash Flow | $ -1.32M | $ 9.06M | $ -25.97M | $ 62.52M | $ -38.41M |
| Financing Cash Flow | $ 10.38M | $ 6.45M | $ 360.00K | $ 150.00K | $ 60.98M |